A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Multiple myeloma (MM) is the second most common hematological malignancy and is still incurable. Positron emission tomography/computed tomography (PET/CT) has been used to diagnose, assess treatment response, and predict prognosis in MM. 18F-fluorodeoxyglucose (FDG) is the most widely used radiotracer, but there is heterogeneous uptake in MM, that is, uptake is negative in some myeloma cells. There are currently reports of cases with strong uptake of prostate-specific membrane antigen (PSMA) PET/CT in MM. Therefore, this preliminary study was designed to compare the imaging results of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT, and to evaluate the additional value of 18F-PSMA-1007 PET/CT to 18F-FDG PET/CT in MM.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Hospital of China Medical University
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• confirmed untreated or relapsed multiple myeloma patients;

• 18F-PSMA-1007 and 18F-FDG PET/CT within one week;

• signed written consent;

• no combined other Malignant tumors.

Exclusion Criteria:

• suffered from arthritis or combined with other malignant tumors;

• received myeloma-related therapy whinin 3 months before PET/CT imaging

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.